Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

lnacipran were sustained for up to one year of therapy.

"Because patients with fibromyalgia experience a wide array of symptoms that can overlap with other conditions, diagnosis and treatment can be complicated. Currently, many doctors are using multiple medications to treat the various symptoms of fibromyalgia," said Daniel J. Clauw, MD, lead investigator, Chronic Pain and Fatigue Research Center, University of Michigan. "There is a real unmet need for a therapy that not only relieves pain but addresses the functional and physical aspects of the illness that can have a significant impact on a patient's quality of life."

Study Methodology

In two double-blind, placebo-controlled, pivotal Phase III studies (Study MLN-MD-02 and Study FMS-031), the two parallel, primary efficacy assessments consisted of composite responder analyses for the treatment of both fibromyalgia syndrome and the pain of fibromyalgia. Pain composite responders were defined as individuals who achieved both a greater than or equal to 30% reduction in pain compared to baseline as measured by a visual analog scale recorded daily on an electronic patient experience diary, and who rated themselves as "very much improved" or "much improved" on a Patient Global Impression of Change (PGIC) scale. Fibromyalgia syndrome composite responders needed to satisfy the pain composite criteria as well as demonstrate at least a 6-point improvement in their SF-36 physical component summary (SF-36 PCS) score.

In Study MLN-MD-02, 1196 patients were randomized to receive either milnacipran 100 mg/day (n=399), 200 mg/day (n=396) or placebo (n=401) over a three-month period, 67.7% of whom completed the trial.

In Study FMS-031, 888 patients were randomized to receive either milnacipran 100 mg/day (n=224), 200 mg/day (n=441) or placebo (n=223) for six- months, 63.6% of whom completed three-months of treatment, and 57.6% of whom completed the full six-months of double-blind treatment. Results we
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Cochlear Limited ... hearing solutions, announced today the US Food and ... Profile™ Implant with Slim Straight Electrode (CI522). Built ... in close collaboration with the world,s leading surgeons, ... platform designed to provide the most discreet appearance ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/34xqr7/2015_new ) has announced the addition of ... Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, ... their offering. 2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape is ...
(Date:7/1/2015)... July 1, 2015  goBalto, Inc., the leading ... today unprecedented growth in serving pharmaceutical, biotech and ... to speed clinical trials and restrain costs, but ... methods have stalled these efforts," said Sujay ... clinical trials has encouraged Industry leaders, to embrace ...
Breaking Medicine Technology:Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 32015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2
(Date:7/1/2015)... ... 2015 , ... As if mood swings, cramps and child labor weren’t enough ... leg pain. Northeast Houston Vein Center is offering tips on the treatment options for ... is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, restless legs, cramps ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of IBM software products, announced today that it has received trademark protection for ... display and detailed analysis of data from multiple sources providing an environment where ...
(Date:7/1/2015)... ... 2015 , ... A Priority Setting Partnership put in place ... they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted an ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the mesothelioma ...
(Date:7/1/2015)... York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t ... fell into her lap, so too did her support of the practice; a terrible car ... , In her new book, “Do I Need It ? (And What if I ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... the battle against malignant brain tumors, dual implantation ... showed promising results in a study led by ... of Cincinnati (UC) and University Hospital. , The ... Journal of Neurosurgery, revealed that patients treated with ...
... Gornick LLP, Bailey Perrin Bailey LLP and Weitz &, ... United, States District Court for the Eastern District of New York ... Co., Inc. and Schering-Plough Corporation., ... the law,firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, ...
... Five Such Cases Known Worldwide, NEW HYDE PARK, N.Y., ... physicians at LIJ Medical,Center, 25-year-old Stacey Gayle can now look ... radio. At a news conference today, Ms.,Gayle and her doctors ... robbed her of her health, but of the very important,gift ...
... Jan Marini Skin Research,Inc. (JMSR; http://www.janmarini.com ) today ... Age Intervention Eyelash Conditioner,and Age Intervention Masses of Lashes ... patent infringement lawsuit by Allergan Pharmaceutical as,one reason for ... suspend,these products while we strategically review our options," said ...
... general use, experts caution , , THURSDAY, Jan. 17 (HealthDay News)-- Some ... modifies the body,s immune response. , A study in the Jan. ... no history of heart attacks, as well as those in a ... and of subsequent hospitalizations with such a treatment. , But ...
... a lack of knowledge of health risks posed by ... cell phone technology and use continues to expand and evolve, ... potential health risks associated with long-term exposure to radiofrequency energy. ... women and fetuses -- as well as workers subject to ...
Cached Medicine News:Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music 2Health News:Jan Marini Skin Research Suspends Sales of Popular Eyelash Products 2Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: